Compare Bank of America Corp (BAC) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs BioNTech SE - ADR — how do they compare? Bank of America Corp trades at $60.79 (market cap $425.43B), while BioNTech SE - ADR trades at $89.89 (market cap $22.86B). The key difference: Bank of America Corp is far larger — about 18.6× BioNTech SE - ADR's market cap, and Bank of America Corp pays a 1.85% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BAC | BNTX | |
|---|---|---|
Market Cap | $425.43B | $22.86B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $60.62 | $119.34 |
52-Week Low | $44.92 | $83.89 |
Dividend Yield | 1.85% | — |
Enterprise Value | — | $6.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $60.62, up 1.59% today, with a bullish technical signal from moving averages and a consensus analyst price target of $63.79. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.11 exceeding expectations. Revenue grew to $113.10 billion in 2025, and the company maintains a strong deposit franchise, as highlighted by recent news coverage.
The outlook is positive, supported by earnings momentum and potential capital returns post-stress tests. Risks include macroeconomic sensitivity and regulatory changes. Analyst sentiment is strongly bullish, with 65% recommending Buy.
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
